Alembic Pharma arm inks pact with Curon to develop cancer treatment drug in Greater China

Alembic Pharma arm inks pact with Curon to develop cancer treatment drug in Greater China According to a regulatory filing, Rhizen Pharmaceuticals is a Switzerland-based privately held clinical-stage biopharmaceutical company, and Curon Biopharmaceutical is a clinical-stage innovative biopharmaceutical company with facility in Shanghai.

No comments:

Post a Comment